Logo image of MRX

MAREX GROUP PLC (MRX) Stock Fundamental Analysis

NASDAQ:MRX - Nasdaq - GB00BMT7GT62 - Common Stock - Currency: USD

37.03  -1.78 (-4.59%)

After market: 37.03 0 (0%)

Fundamental Rating

3

Taking everything into account, MRX scores 3 out of 10 in our fundamental rating. MRX was compared to 225 industry peers in the Capital Markets industry. MRX has a bad profitability rating. Also its financial health evaluation is rather negative. MRX has a decent growth rate and is not valued too expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRX had positive earnings in the past year.
MRX had a positive operating cash flow in the past year.
MRX Yearly Net Income VS EBIT VS OCF VS FCFMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 200M -200M 400M 600M

1.2 Ratios

MRX has a worse Return On Assets (1.30%) than 64.38% of its industry peers.
The Return On Equity of MRX (25.42%) is better than 93.15% of its industry peers.
Industry RankSector Rank
ROA 1.3%
ROE 25.42%
ROIC N/A
ROA(3y)0.79%
ROA(5y)N/A
ROE(3y)13.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MRX Yearly ROA, ROE, ROICMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 5 10 15

1.3 Margins

With a Profit Margin value of 7.95%, MRX is not doing good in the industry: 64.84% of the companies in the same industry are doing better.
The Gross Margin of MRX (38.61%) is worse than 68.04% of its industry peers.
Industry RankSector Rank
OM N/A
PM (TTM) 7.95%
GM 38.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRX Yearly Profit, Operating, Gross MarginsMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 0 20 -20 40

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for MRX remains at a similar level compared to 1 year ago.
Compared to 1 year ago, MRX has a worse debt to assets ratio.
MRX Yearly Shares OutstandingMRX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 20M 40M 60M
MRX Yearly Total Debt VS Total AssetsMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 5B 10B 15B

2.2 Solvency

MRX has an Altman-Z score of 0.30. This is a bad value and indicates that MRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MRX (0.30) is worse than 73.97% of its industry peers.
The Debt to FCF ratio of MRX is 23.78, which is on the high side as it means it would take MRX, 23.78 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of MRX (23.78) is comparable to the rest of the industry.
A Debt/Equity ratio of 8.14 is on the high side and indicates that MRX has dependencies on debt financing.
MRX has a Debt to Equity ratio of 8.14. This is amonst the worse of the industry: MRX underperforms 89.50% of its industry peers.
Industry RankSector Rank
Debt/Equity 8.14
Debt/FCF 23.78
Altman-Z 0.3
ROIC/WACCN/A
WACCN/A
MRX Yearly LT Debt VS Equity VS FCFMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 200M 400M 600M 800M

2.3 Liquidity

MRX has a Current Ratio of 1.09. This is a normal value and indicates that MRX is financially healthy and should not expect problems in meeting its short term obligations.
MRX has a Current ratio (1.09) which is comparable to the rest of the industry.
MRX has a Quick Ratio of 1.08. This is a normal value and indicates that MRX is financially healthy and should not expect problems in meeting its short term obligations.
MRX has a Quick ratio (1.08) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.08
MRX Yearly Current Assets VS Current LiabilitesMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 5B 10B 15B

More info and screens

4

3. Growth

3.1 Past

MRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 39.74%, which is quite impressive.
MRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 79.48%.
EPS 1Y (TTM)39.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.38%
Revenue 1Y (TTM)79.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-53.26%

3.2 Future

The Earnings Per Share is expected to grow by 25.62% on average over the next years. This is a very strong growth
MRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.59% yearly.
EPS Next Y66.33%
EPS Next 2Y30.32%
EPS Next 3Y25.62%
EPS Next 5YN/A
Revenue Next Year-10.65%
Revenue Next 2Y-2.6%
Revenue Next 3Y1.59%
Revenue Next 5YN/A

3.3 Evolution

MRX Yearly Revenue VS EstimatesMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 500M 1B 1.5B
MRX Yearly EPS VS EstimatesMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 1 2 3

More info and screens

5

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 12.06 indicates a correct valuation of MRX.
MRX's Price/Earnings is on the same level as the industry average.
When comparing the Price/Earnings ratio of MRX to the average of the S&P500 Index (29.63), we can say MRX is valued rather cheaply.
A Price/Forward Earnings ratio of 12.06 indicates a correct valuation of MRX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MRX is on the same level as its industry peers.
When comparing the Price/Forward Earnings ratio of MRX to the average of the S&P500 Index (22.68), we can say MRX is valued slightly cheaper.
Industry RankSector Rank
PE 12.06
Fwd PE 12.06
MRX Price Earnings VS Forward Price EarningsMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, MRX is valued a bit cheaper than 77.17% of the companies in the same industry.
Industry RankSector Rank
P/FCF 7.14
EV/EBITDA N/A
MRX Per share dataMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40

4.3 Compensation for Growth

MRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
MRX's earnings are expected to grow with 25.62% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.18
PEG (5Y)N/A
EPS Next 2Y30.32%
EPS Next 3Y25.62%

More info and screens

1

5. Dividend

5.1 Amount

With a Yearly Dividend Yield of 1.44%, MRX has a reasonable but not impressive dividend return.
MRX's Dividend Yield is slightly below the industry average, which is at 10.00.
MRX's Dividend Yield is slightly below the S&P500 average, which is at 2.29.
Industry RankSector Rank
Dividend Yield 1.44%

5.2 History

MRX does not have a reliable dividend history as it only pays dividend since a couple or years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
MRX Yearly Dividends per shareMRX Yearly Dividends per shareYearly Dividends per share 2024 0.05 0.1 0.15 0.2 0.25

5.3 Sustainability

DPN/A
EPS Next 2Y30.32%
EPS Next 3Y25.62%
MRX Yearly Income VS Free CF VS DividendMRX Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2021 2022 2023 200M 400M 600M

More info and screens

MAREX GROUP PLC

NASDAQ:MRX (2/21/2025, 8:00:01 PM)

After market: 37.03 0 (0%)

37.03

-1.78 (-4.59%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryCapital Markets
Earnings (Last)11-07 2024-11-07/bmo
Earnings (Next)N/A N/A
Inst Owners44.65%
Inst Owner Change0%
Ins Owners5.89%
Ins Owner ChangeN/A
Market Cap2.60B
Analysts83.33
Price Target38.38 (3.65%)
Short Float %0.49%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield 1.44%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)11.48%
PT rev (3m)21.93%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-8.25%
EPS NY rev (1m)0.73%
EPS NY rev (3m)1.73%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.21%
Revenue NY rev (1m)0.32%
Revenue NY rev (3m)0.9%
Valuation
Industry RankSector Rank
PE 12.06
Fwd PE 12.06
P/S 0.92
P/FCF 7.14
P/OCF 6.82
P/B 2.95
P/tB 3.94
EV/EBITDA N/A
EPS(TTM)3.07
EY8.29%
EPS(NY)3.07
Fwd EY8.29%
FCF(TTM)5.19
FCFY14.01%
OCF(TTM)5.43
OCFY14.66%
SpS40.15
BVpS12.55
TBVpS9.41
PEG (NY)0.18
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 1.3%
ROE 25.42%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 7.95%
GM 38.61%
FCFM 12.92%
ROA(3y)0.79%
ROA(5y)N/A
ROE(3y)13.95%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.16
Health
Industry RankSector Rank
Debt/Equity 8.14
Debt/FCF 23.78
Debt/EBITDA N/A
Cap/Depr 61.82%
Cap/Sales 0.6%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality 162.55%
Current Ratio 1.09
Quick Ratio 1.08
Altman-Z 0.3
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)64.75%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.84%
Cap/Sales(5y)N/A
Profit Quality(3y)540.38%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.38%
EPS Next Y66.33%
EPS Next 2Y30.32%
EPS Next 3Y25.62%
EPS Next 5YN/A
Revenue 1Y (TTM)79.48%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-53.26%
Revenue Next Year-10.65%
Revenue Next 2Y-2.6%
Revenue Next 3Y1.59%
Revenue Next 5YN/A
EBIT growth 1Y-314.67%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year189.16%
EBIT Next 3Y45.23%
EBIT Next 5YN/A
FCF growth 1Y234.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y225.8%
OCF growth 3YN/A
OCF growth 5YN/A